Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study

Alzheimer's Disease Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02018913
• Other study ID #: NL46089.068.13
• Status: Not yet recruiting
• Phase: N/A
• First received: December 11, 2013
• Last updated: December 17, 2013
• Start date: April 2014
• Est. completion date: April 2018

Study information

• Verified date: December 2013
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Maastricht University Medical Center
• Study type: Observational

Clinical Trial Summary

Alzheimer's disease (AD) and vascular dementia (VaD) are the most common forms of dementia. Yet, the cause of these diseases is still unknown. A potentially important initiating factor is a disrupted blood-brain barrier. This can initiate cerebral microangiopathy, which has frequently been associated with VaD. Nevertheless, also in most AD patients a substantial increase of vascular damage has been observed. The present study investigates the correlation between blood-brain-barrier breakdown and cognitive decline in AD and VaD. An innovative dynamic contrast-enhanced MRI scan that has recently been developed and tested at our institute, will be used to measure blood-brain barrier permeability.

Objective: We will investigate the relationship between this permeability measure and (i) cognitive performance and (ii) the status of MRI visible cerebrovascular pathology (i.e. white matter hyperintensities, lacunar infarctions, microbleeds) in the most common forms of dementia.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 140
• Est. completion date: April 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

Patients:

• Informed consent before participation in the study

• Age of 55 and older

• Diagnosed with AD, VaD, mixed AD and VaD, mild cognitive impairment, vascular cognitive impairment and subjective cognitive impairment

• MMSE = 20 and patients are mentally competent (in general, individuals with an MMSE =18 are considered mentally competent)

Healthy participants:

• Informed consent before participation in the study

• Age of 55 and older

• No Diagnosis of dementia, prodromal dementia, or mild cognitive impairment.

• MMSE = 26

• No substantial memory complaints (according to participant)

• Average age, gender and education is similar to the patient groups.

Exclusion Criteria:

• Contraindications for scanning (e.g. brain surgery, cardiac pacemaker, metal implants, claustrophobia, large body tattoos)

• Contraindications for contrast agent Gadovist (renal failure) as determined by the estimated Glomular Filtration Rate eGFR < 30 mL/min; or known allergy to Gadovist. If participants have a low renal function as determined by <30 GFR <60, the PI will contact a radiologist (Paul Hofman). The radiologist will decide if this patient should be excluded.

• Major vascular disorders (e.g. stroke, heart disease)

• Psychiatric or neurological disorders: Major depression (< 12 months); history of schizophrenia; bipolar disorder; psychotic disorder NOS or treatment for a psychotic disorder (< 12 mnd); cognitive impairment due to alcohol abuse; epilepsy; Parkinson's disease; MS; brain surgery; brain trauma; electroshock therapy; kidney dialysis; Meniere's disease; and brain infections.

• Structural abnormalities of the brain

• Cognitive impairment due to alcohol/drug abuse or abuse of other substances.

• Absence of reliable informant (for patient groups)

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Dementia
• Dementia, Vascular
• Vascular Dementia

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Maastricht University Medical Center	Netherlands Alzheimer Foundation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood brain barrier permeability as measured by T1-weighted dynamic contrast MRI		Up to 4 years: April 2014-April 2018	No